InflaRx N.V. – NASDAQ:IFRX

InflaRx N.V. stock price today

$0.865
-1.72
-66.62%
Financial Health
0
1
2
3
4
5
6
7
8
9

InflaRx N.V. stock price monthly change

+58.90%
month

InflaRx N.V. stock price quarterly change

+58.90%
quarter

InflaRx N.V. stock price yearly change

+43.09%
year

InflaRx N.V. key metrics

Market Cap
141.91M
Enterprise value
203.61M
P/E
-7.55
EV/Sales
N/A
EV/EBITDA
-6.08
Price/Sales
N/A
Price/Book
1.88
PEG ratio
-0.59
EPS
-0.69
Revenue
N/A
EBITDA
-43.51M
Income
-40.88M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

InflaRx N.V. stock price history

InflaRx N.V. stock forecast

InflaRx N.V. financial statements

InflaRx N.V. (NASDAQ:IFRX): Profit margin
Jun 2023 0 -8.20M
Sep 2023 60.80K -7.45M -12255%
Dec 2023 2.22K -15.52M -696965.02%
Mar 2024 36.24K -9.71M -26798.21%
InflaRx N.V. (NASDAQ:IFRX): Analyst Estimates
Dec 2023 2.22K -15.52M -696965.02%
Mar 2024 36.24K -9.71M -26798.21%
Sep 2025 324.71K -14.39M -4433.97%
Dec 2025 689.52K -14.97M -2171.57%
  • Analysts Price target

  • Financials & Ratios estimates

InflaRx N.V. (NASDAQ:IFRX): Debt to assets
Jun 2023 132964505 8.31M 6.26%
Sep 2023 129485304 11.49M 8.88%
Dec 2023 120307660 17.64M 14.66%
Mar 2024 107194489 12.34M 11.52%
InflaRx N.V. (NASDAQ:IFRX): Cash Flow
Jun 2023 -11.16M -24.30M 53.14M
Sep 2023 -5.25M 7.37M -94.28K
Dec 2023 -10.29M 2.98M -94.90K
Mar 2024 -14.95M 27.10M -86.21K

InflaRx N.V. alternative data

InflaRx N.V. (NASDAQ:IFRX): Employee count
Aug 2023 44
Sep 2023 44
Oct 2023 44
Nov 2023 44
Dec 2023 44
Jan 2024 44
Feb 2024 44
Mar 2024 62
Apr 2024 62
May 2024 62
Jun 2024 62
Jul 2024 62

InflaRx N.V. other data

1.64% -7.27%
of IFRX is owned by hedge funds
683.76K -3.02M
shares is hold by hedge funds
Friday, 20 December 2024
globenewswire.com
Friday, 15 November 2024
globenewswire.com
Friday, 8 November 2024
zacks.com
globenewswire.com
Wednesday, 25 September 2024
globenewswire.com
Tuesday, 24 September 2024
247wallst.com
Tuesday, 3 September 2024
globenewswire.com
Tuesday, 27 August 2024
globenewswire.com
Thursday, 8 August 2024
zacks.com
globenewswire.com
Thursday, 1 August 2024
globenewswire.com
Monday, 24 June 2024
globenewswire.com
Wednesday, 5 June 2024
globenewswire.com
Tuesday, 21 May 2024
globenewswire.com
Wednesday, 8 May 2024
globenewswire.com
Wednesday, 24 April 2024
globenewswire.com
Thursday, 21 March 2024
Zacks Investment Research
Tuesday, 19 March 2024
GlobeNewsWire
Friday, 1 December 2023
Zacks Investment Research
Tuesday, 28 November 2023
Zacks Investment Research
Monday, 6 November 2023
Zacks Investment Research
Wednesday, 6 September 2023
Seeking Alpha
Friday, 1 September 2023
Zacks Investment Research
Friday, 7 April 2023
The Motley Fool
Wednesday, 5 April 2023
Proactive Investors
Zacks Investment Research
The Motley Fool
InvestorPlace
Wednesday, 14 December 2022
Seeking Alpha
Friday, 9 September 2022
GlobeNewsWire
  • What's the price of InflaRx N.V. stock today?

    One share of InflaRx N.V. stock can currently be purchased for approximately $0.86.

  • When is InflaRx N.V.'s next earnings date?

    Unfortunately, InflaRx N.V.'s (IFRX) next earnings date is currently unknown.

  • Does InflaRx N.V. pay dividends?

    No, InflaRx N.V. does not pay dividends.

  • How much money does InflaRx N.V. make?

    InflaRx N.V. has a market capitalization of 141.91M.

  • What is InflaRx N.V.'s stock symbol?

    InflaRx N.V. is traded on the NASDAQ under the ticker symbol "IFRX".

  • What is InflaRx N.V.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of InflaRx N.V.?

    Shares of InflaRx N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does InflaRx N.V. have?

    As Jul 2024, InflaRx N.V. employs 62 workers.

  • When InflaRx N.V. went public?

    InflaRx N.V. is publicly traded company for more then 7 years since IPO on 7 Nov 2017.

  • What is InflaRx N.V.'s official website?

    The official website for InflaRx N.V. is inflarx.de.

  • How can i contact InflaRx N.V.?

    InflaRx N.V. can be reached via phone at +49 3641 508180.

InflaRx N.V. company profile:

InflaRx N.V.

inflarx.de
Exchange:

NASDAQ

Full time employees:

62

Industry:

Biotechnology

Sector:

Healthcare

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Winzerlaer Str. 2
Jena, 07745

CIK: 0001708688
ISIN: NL0012661870
CUSIP: N44821101